Editorial
Treatment of psoriatic arthritis: Challenges in Latin America
Tratamiento de la artritis psoriásica: retos y desafíos en Latino América
Wilson Bautista Molano
Hospital Universitario Fundación Santa Fe de Bogotá, Universidad El Bosque, Bogotá, Colombia
Read
2942
Timeswas read the article
1211
Total PDF
1731
Total HTML
Share statistics
array:23 [ "pii" => "S2173574321001155" "issn" => "21735743" "doi" => "10.1016/j.reumae.2021.03.003" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1528" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2021" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2021;17:307-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X21000954" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2021.03.006" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1528" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2021;17:307-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Tratamiento de la Artritis Psoriásica: Retos y Desafíos en Latino América" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "307" "paginaFinal" => "308" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment of Psoriatic Arthritis: Challenges in Latin America" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Wilson Bautista-Molano" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Wilson" "apellidos" => "Bautista-Molano" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574321001155" "doi" => "10.1016/j.reumae.2021.03.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321001155?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X21000954?idApp=UINPBA00004M" "url" => "/1699258X/0000001700000006/v1_202105200700/S1699258X21000954/v1_202105200700/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574321000952" "issn" => "21735743" "doi" => "10.1016/j.reumae.2020.04.012" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1420" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2021;17:309-12" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "309" "paginaFinal" => "312" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4368 "Ancho" => 2917 "Tamanyo" => 856614 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Pathophysiology of ARDS. The initial inflammatory stimulus activates alveolar macrophages through TLR and NLRP signalling. Activated alveolar macrophages release proinflammatory cytokines and recruit circulating macrophages and neutrophils to injury sites. This influx of persistently activated neutrophils and macrophages causes extensive damage to epithelial and endothelial lung tissue, resulting in an impaired alveolar-capillary barrier.</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">ENaC: Epithelial sodium channel; Na: Sodium; NETs: Neutrophil Extracellular Traps; TLR: Toll-like receptor; U: Ubiquitination.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Source: version adapted from the original by Seung Hye Han et al. Scientific illustrator: Miguel Soto.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alejandro Muñoz-Jiménez, Esteban Rubio-Romero, José Luis Marenco de la Fuente" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Muñoz-Jiménez" ] 1 => array:2 [ "nombre" => "Esteban" "apellidos" => "Rubio-Romero" ] 2 => array:2 [ "nombre" => "José Luis Marenco de la" "apellidos" => "Fuente" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X20300863" "doi" => "10.1016/j.reuma.2020.04.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20300863?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321000952?idApp=UINPBA00004M" "url" => "/21735743/0000001700000006/v1_202105240506/S2173574321000952/v1_202105240506/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Treatment of psoriatic arthritis: Challenges in Latin America" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "307" "paginaFinal" => "308" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Wilson Bautista Molano" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Wilson Bautista" "apellidos" => "Molano" "email" => array:1 [ 0 => "wilson.bautista@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Hospital Universitario Fundación Santa Fe de Bogotá, Universidad El Bosque, Bogotá, Colombia" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de la artritis psoriásica: retos y desafíos en Latino América" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Psoriatic Arthritis (PsA is a chronic inflammatory disease of the musculoskeletal system belonging to the family of spondyloarthritis. It presents in 30% of patients with platelet psoriasis, particularly in those with nail bed compromise and with location of the psoriasis in certain anatomical areas (e.g. scalp). It affects between .05% and .25% of the general population,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> which makes it the second most common form of chronic inflammatory arthritis after rheumatoid arthritis. PsA comprises several domains which represent the phenotypic manifestations of the disease. It usually aggravates skin psoriasis and often presents as an oligoarthritis with dactylitis, enthesitis and/or extra-articular-associated axial compromise, which included uveitis and/or inflammatory bowel disease. Its varied forms of presentation and manifestations, both musculoskeletal and cutaneous, make its therapeutic focus hugely complex, often requiring a multidisciplinary approach.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> In order to approach the therapeutic options and integrate the musculoskeletal and cutaneous phenotypes, the GRAPPA group (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) identified six disease domains (peripheral arthritis, enthesitis, dactylitis, axial compromise, psoriasis and nail bed compromise.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Available information in the literature regarding prevalence, incidence, phenotypic presentation and response to treatment in developing countries is scarce. Management recommendations for PsA from GRAPPA<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> and EULAR<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> (European League Against Rheumatism), have been developed based on information from studies originating from Europe and North America. These recommendations have often been adapted to the context of the health systems and patients in the different developing countries. However, there are no recommendations which specifically focus on the treatment of PsA in countries with limited resources.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Bearing in mind the above, a group of members from the ILAR (International League of Associations for Rheumatology) worked on creating recommendations for the treatment of PsA, in regions of the world where several of the recommended treatments had access limitations or their use was conditioned by the presence of infectious diseases and/or comorbidities.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The group called <span class="elsevierStyleItalic">ILAR-PsA</span> comprised rheumatologists and dermatologists from Latin American and Africa countries with clinical expertise in the treatment of PsA and Psoriasis. The Asia Pacific region was not represented in the group because the APLAR (Asia Pacific League of Associations for Rheumatology) was in the process of writing its own guidelines.</p><p id="par0020" class="elsevierStylePara elsevierViewall">To adapt the existing GRAPPA and EULAR guidelines, the <span class="elsevierStyleItalic">ILAR-PsA</span> recommendation group used the <span class="elsevierStyleItalic">ADAPTE</span> process for the development of clinical practice guidelines. In order to generate recommendations, they identified specific areas of unmet needs and exclusive challenges pertaining to countries with limited resources. The work group discussed the relevant questions of diagnosis and treatment approach and they reviewed the EULAR and GRAPPA recommendations for clinical content in accordance with the approved questions. Following an iterative process, 10 questions were identified with under 70% agreement between committee members, and this therefore required a systematic review of the literature. Despite an exhaustive review of databases (including, among others, the African Index Medicus, and Latin American and Caribbean Healthcare Literature), no published information was found to have come from regions with limited resources. The recommendations relating to these questions were therefore adapted based on the expert opinions.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The recommendation group evaluated the need for early diagnosis and the use of disease-modifying drugs (in monotherapy or combined therapy), to obtain control of the disease in regions with limited access to biologics and with specific comorbidities which would be potentially included in clinical decisions. The importance of monitoring the efficacy and safety of the said drugs was emphasized, including follow-up of adverse events. Equally, patient access limitations were discussed by both speciality healthcare professionals, rheumatologists and dermatologists. Follow-up of comorbidities and the need for a multidisciplinary team to manage a heterogeneous and complex disease was also highlighted. Finally, the prevalence of infections was considered (including tuberculosis), which is higher in developing countries. However, there is very little information available which evaluates the prevalence of these infections in patients with PsA in these regions. This is relevant in the setting of the use of biologic therapy (e.g. anti TNF),<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> as it may increase the risk of active tuberculosis. Other infections include Chagas disease, leishmaniasis, hepatitis B, hepatitis C and leprosy. In these cases, follow-up of national directives were recommended for each of these conditions prior to initiation of treatment.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Several studies have been conducted in Latin America aimed at filling in the information gaps on PsA. Studies have been published which evaluate the epidemiological profile and prevalence of patients with spondyloarthritis including PsA.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Other studies have estimated that the incidence and prevalence may be similar to that reported in Europe and the United States,<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> and usage frequency of treatment options in daily clinical practice has been estimated.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Additional studies have also explored the levels of satisfaction given by the doctor and patient with regards to PsA treatment.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">To sum up, the recommendations of the <span class="elsevierStyleItalic">ILAR-PsA</span> group were specifically geared towards region of the world with limited human and economic resources. They provide additional relevant information for the specific environments of these countries and they seek to unify PsA treatment in a complementary fashion to national guidelines of these countries when they are available. We would emphasize the importance of supranational scientific societies such as PANLAR (Pan American League of Associations of Rheumatology) in creating guidelines for PsA management where the particularities of these countries are considered.</p><p id="par0040" class="elsevierStylePara elsevierViewall">One of the main results from this adaptation exercise was the acknowledgement of the scarcity of information in the context of PsA patients in regions with limited resources, including Latin American. In this sense there is clearly a need to design and produce a research plan to provide relevant data and to identify not only epidemiological aspects — such as prevalence, extra-articular manifestations, structural damage, comorbidities-, but to also calculate delay in diagnosis, patient perspective, medical outcomes, response to treatment and the safety of pharmacological interventions in patients with PsA. The need also arises for the evaluation of these recommendations, in the light of the recent new evidence arising. We hope this document serves as a wake-up call to rheumatologists, researchers and financial entities in Latin American to recognise these shortcomings and to provide evidence through a research plan so that by fortifying these and future recommendations in PsA any unmet needs may be resolved.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Molano WB. Tratamiento de la Artritis Psoriásica: Retos y Desafíos en Latino América. Reumatol Clin. 2021;17:307–308.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The epidemiology of psoriatic arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Ogdie" 1 => "P. Weiss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rdc.2015.07.001" "Revista" => array:5 [ "tituloSerie" => "Rheumat Dis Clinics North Am" "fecha" => "2015" "volumen" => "41" "paginaInicial" => "545" "paginaFinal" => "568" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de Práctica Clínica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psoriásica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Cañete Crespillo" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Soc Española Reumatol" "fecha" => "2015" "paginaInicial" => "1" "paginaFinal" => "206" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://www.ser.es/wp-content/uploads/2016/04/GPC_Tratamiento_EspAax_APs_DEF.pdf" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.C. Coates" 1 => "A. Kavanaugh" 2 => "P.J. Mease" 3 => "E.R. Soriano" 4 => "M. Laura Acosta-Felquer" 5 => "A.W. Armstrong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39573" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2016" "volumen" => "68" "paginaInicial" => "1060" "paginaFinal" => "1071" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26749174" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Gossec" 1 => "J.S. Smolen" 2 => "S. Ramiro" 3 => "M. de Wit" 4 => "M. Cutolo" 5 => "M. Dougados" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2015-208337" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2016" "volumen" => "75" "paginaInicial" => "499" "paginaFinal" => "510" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26644232" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Elmamoun" 1 => "M. Eraso" 2 => "M. Anderson" 3 => "A. Maharaj" 4 => "L. Coates" 5 => "V. Chandran" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-020-04934-7" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2020" "volumen" => "39" "paginaInicial" => "1839" "paginaFinal" => "1850" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31950441" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Bautista-Molano" 1 => "R. Landewé" 2 => "R. Burgos-Vargas" 3 => "J. Maldonado-Cocco" 4 => "A. Moltó" 5 => "F. van den Bosch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.170520" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "206" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29247152" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Citera" 1 => "W. Bautista-Molano" 2 => "I. Peláez-Ballestas" 3 => "V.F. Azevedo" 4 => "R.A. Perich" 5 => "J.A. Méndez-Rodríguez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s42358-020-00161-5" "Revista" => array:5 [ "tituloSerie" => "Adv Rheumatol" "fecha" => "2021" "volumen" => "61" "paginaInicial" => "2" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33419481" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.R. Soriano" 1 => "J. Rosa" 2 => "E. Velozo" 3 => "M. Schpilberg" 4 => "P.M. Imamura" 5 => "J. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keq369" "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2011" "volumen" => "50" "paginaInicial" => "729" "paginaFinal" => "734" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Aimo" 1 => "V.L. Cosentino" 2 => "G. Sequeira" 3 => "E. Kerzberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-019-04266-z" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2019" "volumen" => "39" "paginaInicial" => "723" "paginaFinal" => "727" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30830285" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Er Soriano" 1 => "F. Zazzetti" 2 => "I. Alves Pereira" 3 => "J. Maldonado Cocco" 4 => "V. Feijó Azevedo" 5 => "G. Guerra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-019-04870-1" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2020" "volumen" => "39" "paginaInicial" => "1859" "paginaFinal" => "1869" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31993888" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001700000006/v1_202105240506/S2173574321001155/v1_202105240506/en/main.assets" "Apartado" => array:4 [ "identificador" => "17335" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001700000006/v1_202105240506/S2173574321001155/v1_202105240506/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321001155?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 4 | 9 |
| 2024 October | 65 | 24 | 89 |
| 2024 September | 53 | 20 | 73 |
| 2024 August | 58 | 41 | 99 |
| 2024 July | 47 | 26 | 73 |
| 2024 June | 47 | 33 | 80 |
| 2024 May | 46 | 35 | 81 |
| 2024 April | 55 | 26 | 81 |
| 2024 March | 54 | 29 | 83 |
| 2024 February | 53 | 33 | 86 |
| 2024 January | 43 | 40 | 83 |
| 2023 December | 34 | 49 | 83 |
| 2023 November | 45 | 63 | 108 |
| 2023 October | 45 | 31 | 76 |
| 2023 September | 64 | 39 | 103 |
| 2023 August | 53 | 16 | 69 |
| 2023 July | 41 | 27 | 68 |
| 2023 June | 58 | 26 | 84 |
| 2023 May | 45 | 34 | 79 |
| 2023 April | 39 | 17 | 56 |
| 2023 March | 49 | 26 | 75 |
| 2023 February | 50 | 35 | 85 |
| 2023 January | 33 | 33 | 66 |
| 2022 December | 60 | 36 | 96 |
| 2022 November | 64 | 31 | 95 |
| 2022 October | 62 | 33 | 95 |
| 2022 September | 43 | 26 | 69 |
| 2022 August | 44 | 47 | 91 |
| 2022 July | 32 | 38 | 70 |
| 2022 June | 35 | 27 | 62 |
| 2022 May | 48 | 47 | 95 |
| 2022 April | 38 | 44 | 82 |
| 2022 March | 66 | 51 | 117 |
| 2022 February | 59 | 42 | 101 |
| 2022 January | 50 | 34 | 84 |
| 2021 December | 46 | 45 | 91 |
| 2021 November | 2 | 3 | 5 |
Show all
